Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives

• Published in: Neurobiology of disease Vol. 131; p. 104257
• Main Authors: Nucifora, Frederick C., Woznica, Edgar, Lee, Brian J., Cascella, Nicola, Sawa, Akira
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2019; Elsevier
• Subjects: Brain Imaging; CBT; Clozapine; DBS; Dopamine; Drug Resistance; ECT; Genetics; Glutamate; Humans; Neurobiology; rTMS; Schizophrenia; Schizophrenia - physiopathology; Schizophrenia - therapy; Treatment-Resistant; FDA; RCT; GWAS; Neurobiology; UTRS; Schizophrenia; Brain Imaging; HR; leTPC; BPRS; PRS; Glu; Treatment-Resistant; DBS; CBT; SNP; TRS; MD; Genetics; PANSS; CATIE; Dopamine; NMA; DLPFC; MR; CI; AH; Clozapine; Glutamate; PGC; non-TRS; CR; ECT; SAPS; HC; rTMS; DA; TRRIP

Treatment resistant schizophrenia (TRS) refers to the significant proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment. While many definitions of TRS include failure of two different antipsychotics as a minimum criterion, the wide variability in incl...